SHR6390 + itraconazole

SHR6390 + itraconazole is a combination regimen that includes **SHR6390 (dalpiciclib)**, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, and **itraconazole**, a broad-spectrum triazole antifungal drug. SHR6390 acts by blocking the activity of CDK4 and CDK6, inducing G1 cell cycle arrest and senescence in retinoblastoma (RB)-positive tumor cells, and is primarily aimed at the treatment of hormone receptor positive, HER2-negative advanced breast cancer[1][3]. Itraconazole inhibits fungal 14α-demethylase, thereby blocking ergosterol synthesis, an essential component of the fungal cell membrane[2][4]. This combination is not known to be an approved fixed-dose product but may be studied together due to potential drug-drug interactions, as itraconazole is a strong CYP3A4 inhibitor, which may influence the metabolism and plasma concentration of SHR6390.

Brand names

SporanoxTolsura